A bottle of diphtheria antitoxin, produced by the United States Hygienic Laboratory and dated May 8, 1895
Find information on thousands of medical conditions and prescription drugs.

Diphtheria

Diphtheria is an upper respiratory tract illness characterized by sore throat, low-grade fever, and an adherent membrane of the tonsil(s), pharynx, and/or nose. A milder form of diphtheria can be limited to the skin. It is caused by Corynebacterium diphtheriae, an aerobic Gram-positive bacterium. more...

Home
Diseases
A
B
C
D
Dandy-Walker syndrome
Darier's disease
Dementophobia
Demyelinating disease
Dendrophobia
Dengue fever
Dental fluorosis
Dentinogenesis imperfecta
Dentophobia
Depersonalization disorder
Dermatitis herpetiformis
Dermatofibroma
Dermatographic urticaria
Dermatomyositis
Dermatophytosis
Desmoplastic small round...
Dextrocardia
Diabetes insipidus
Diabetes mellitus
Diabetes, insulin dependent
Diabetic angiopathy
Diabetic nephropathy
Diabetic neuropathy
Diamond Blackfan disease
Diastrophic dysplasia
Dibasic aminoaciduria 2
Diethylstilbestrol...
DiGeorge syndrome
Dilated cardiomyopathy
Diphallia
Diphtheria
Dipsophobia
Dissociative amnesia
Dissociative fugue
Dissociative identity...
Distemper
Diverticulitis
Diverticulosis
Dk phocomelia syndrome
Doraphobia
Double outlet right...
Downs Syndrome
Dracunculiasis
Duane syndrome
Dubin-Johnson syndrome
Dubowitz syndrome
Duchenne muscular dystrophy
Dupuytren's contracture
Dwarfism
Dysbarism
Dysgerminoma
Dyskeratosis congenita
Dyskinesia
Dysmorphophobia
Dysplasia
Dysplastic nevus syndrome
Dysthymia
Dystonia
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Medicines

Diphtheria is a highly contagious disease spread by direct physical contact or breathing the secretions of those infected. Diphtheria was once quite common, but has now largely been eradicated in developed nations (in the United States for instance, there have been fewer than 5 cases a year reported since 1980, as the DPT (Diphtheria-Tetanus-Pertussis) vaccine is given to all school children). Boosters of the vaccine are recommended for adults because the benefits of the vaccine decrease with age; they are particularly recommended for those travelling to areas where the disease has not been eradicated yet.

Signs and symptoms

The respiratory form has an incubation time of 1-4 days. Symptoms include fatigue, fever, a mild sore throat and problems swallowing. Children infected have symptoms that include nausea, vomiting, chills, and a high fever, although some do not show symptoms until the infection has progressed further.

Low blood pressure may develop in some patients. Longer-term effects include cardiomyopathy and peripheral neuropathy (sensory type).

Diagnosis

Laboratory criteria

  • Isolation of Corynebacterium diphtheriae from a clinical specimen, or
  • Histopathologic diagnosis of diphtheria

Case classification

  • Probable: a clinically compatible case that is not laboratory confirmed and is not epidemiologically linked to a laboratory-confirmed case
  • Confirmed: a clinically compatible case that is either laboratory confirmed or epidemiologically linked to a laboratory-confirmed case

Empirical treatment should generally be started in a patient in whom suspicion of diphtheria is high.

Treatment

The disease may remain manageable, but in more severe cases lymph nodes in the neck may swell, and breathing and swallowing will be more difficult. People in this stage should seek immediate medical attention, as obstruction in the throat may require a tracheotomy. In addition, an increase in heart rate may cause cardiac arrest. Diphtheria can also cause paralysis in the eye, neck, throat, or respiratory muscles. Patients with severe cases will be put in ICUs (Intensive Care Units) at hospitals and be given a diphtheria anti-toxin and bactericidal drugs such as penicillin and erythromycin. Bed rest is important and physical activity should be limited, especially in cases where there is inflammation of the heart muscles. Recovery is generally slow.

Epidemiology

Diphtheria remains a serious disease, with 5-10% percent fatality and up to 20% in children younger than 5 or adults older than 40. Outbreaks, though very rare, still can occur worldwide, even in developed nations. After the breakup of the old Soviet Union in the late 1980s, vaccination rates fell so low that there was an explosion of diphtheria cases. In 1991 there were 2,000 cases of diphtheria in Russia and its newer independent states. By 1998 there were as many as 200,000 cases, with 5,000 deaths, according to Red Cross estimates. This was so great an increase that it was cited in the Guinness Book of World Records as "most resurgent disease".

Read more at Wikipedia.org


[List your site here Free!]


Imported cutaneous diphtheria, United Kingdom
From Emerging Infectious Diseases, 3/1/04 by Anne-Claire de Benoist

Cutaneous diphtheria is endemic in tropical countries but unusual in the United Kingdom. Four cases occurred in the United Kingdom within 2 months in 2002. Because cutaneous diphtheria causes outbreaks of both cutaneous and pharyngeal forms, early diagnosis is essential for implementing control measures; high diphtheria vaccination coverage must also be maintained.

**********

We report four cases of cutaneous diphtheria that occurred in the United Kingdom during a 2-month period in 2002 and review past cases.

The Study

Patient 1

In September 2002, a 6-year-old girl appeared for treatment with an infected mosquito bite on the ankle and chest lesions. The lesions developed while she was traveling with her mother and four siblings in Bangladesh. Her 12-year-old sister also had infected mosquito bites on her feet. Swab specimens, taken from the chest lesions and feet, were microbiologically cultured. Staphylococcus aureus, Streptococcus pyogenes, and toxigenic Corynebacterium diphtheriae var mitis were isolated from the specimens. The 6-year-old had received flucloxacillin for 5 days before the antimicrobial agent was changed to erythromycin. She had received three primary doses of diphtheria vaccine at birth, 5 months, and 9 months, and a booster vaccination in 2001. The 12- year-old was initially treated as a contact with 7 days of erythromycin; this treatment was extended to 14 days when the laboratory confirmed C. diphtheriae infection. She had received three primary diphtheria vaccine doses in 1994, but no booster. The children's mother had received one dose of tetanus-diphtheria (Td) toxoid in July 2002, and their mother, a household contact, had no immunization record. The remaining siblings had received at least three primary doses of diphtheria vaccine, and one had received a booster. Nose and throat swabs from all six members of the family, including the two patients, were negative for C. diphtheriae. The four contacts were given antimicrobial prophylaxis and completed immunization as appropriate. The two girls were kept home from school until their antibiotic regimen was completed and clearance swabs of the lesions taken 24 hours apart were confirmed as negative.

Ribotyping, a universal molecular typing method for bacteria based upon rRNA gene restriction pattern determination, was performed on the isolates from the two siblings. The ribotype patterns produced were indistinguishable from each other. The girls' schools were asked for lists of all children who had been in contact with the two patients to establish their diphtheria immunization status as shown on the Child Health System (a population-based register of all children living in each locality, which includes information on vaccination status and other health indices). In addition, an information letter was sent to all parents.

Patient 2

In September 2002, an 8-year-old Somalian girl, who had been in the United Kingdom for 4 months, was hospitalized with lesions on her legs and scalp, a sore throat, but no rever. She had no history of diphtheria immunization. The swabs flora the throat and lesions yielded toxigenic C. diphtheriae var mitis. The organista isolated from the throat was only identified because the microbiology department screened all throat swabs routinely for corynebacteria. S. aureus was also isolated from the skin lesions. She was treated with flucloxacillin and penicillin. The skin lesions had been swabbed before September but had not been examined for C. diphtheriae. The isolates from the throat swab and the lesion were genotyped, and the ribotype patterns that resulted were identical. Two adults and tire unvaccinated siblings were identified as contacts. After screening, all were negative for C. diphtheriae and were offered vaccination.

Patient 3

At the end of October 2002, an 81-year-old man returned to England from Pakistan with an infected mosquito bite. Toxigenic C. diphtheriae var mitis was isolated from the lesion. The patient received diphtheria antitoxin and was treated with erythromycin and clarithromycin for 14 days. He had no history of diphtheria immunization. He had traveled alone to Pakistan. Twelve of his close contacts in the United Kingdom required microbiologic screening, although C. diphtheriae was not isolated from any. The contacts received erythromycin prophylaxis and were offered vaccine, except for two children who had already been vaccinated. Information also was sent to the patient's contacts in Pakistan.

Conclusions

In the United Kingdom, 17 patients with cases of cutaneous diphtheria due to toxigenic C. diphtheriae were reported from 1995 to 2002. All cases were travel-related (Table). Of 15 patients with a vaccination history, 6 were fidly immunized (four primary doses by 5 years of age), 2 had received three doses of vaccine, and 7 had not been vaccinated.

In 1985, one patient with a secondary laryngeal case and a total of 16 carriers, including 8 who were secondary contacts of carriers, were associated with one cutaneous case. Dissemination to children and adults in several classes, schools, and households occurred within just 20 days (1). A patient in 1998 generated two asymptomatic carriers. The two sisters in 2002 acquired their lesions at approximately the same time, and thus we cannot determine whether they were infected by the same source or whether one infected the other.

High vaccination coverage is critical. The greater spread of infection after the 1985 case might be related to lower vaccination coverage at that time. In 1985, primary immunization for diphtheria was 85% compared to the current rate of 94%.

Cutaneous diphtheria, still endemic in tropical countries, is the most common nonrespiratory clinical manifestation of infection due to toxigenic isolates of C. diphtheriae (2). The disease is characterized by shallow skin ulcers, which can occur anywhere on the body and are usually chronic. They are often associated with infected insect bites, frequently coinfected with pathogens such as S. aureus and S. pyogenes. Systemic toxic manifestations are uncommon among immunized persons. Skin lesions absorb toxin slowly and can induce high levels of antibodies that produce natural immunization. These lesions are an important reservoir of infection and can cause respiratory and cutaneous infections in contacts as well as outbreaks (3). In several outbreaks, secondary transmission has been higher in contacts of patients with cutaneous infection than in those with respiratory tract infection. Cutaneous diphtheria may also cause greater environmental contamination, through dust and fomites (4).

Cutaneous diphtheria is still being reported in the United Kingdom, even in vaccinated patients and despite high diphtheria vaccination coverage. All cases so far have been acquired in countries where diphtheria is endemic. With increasing travel to and from these countries, more cases may occur. The potential for secondary transmission leads to a large number of contacts requiring follow-up, especially children at school. Moreover, cutaneous diphtheria is likely to be diagnosed less quickly than respiratory infection because the clinical appearance is nonspecific, and other pathogens often coinfect the lesions. Thus, we need to increase the awareness of clinicians and microbiologists of the importance of obtaining swab specimens from any chronic nonhealing skin lesions in patients who have traveled to a disease-endemic area. Wound swab samples from these patients should be examined for C. diphtheriae. Early diagnoses and reporting are crucial to trigger effective public health control measures (5).

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

References

(1.) Bowler ICJ, Mandal BK, Schlecht B, Riordan T. Diphtheria--the continuing hazard. Short reports. Arch Dis Child 1988;63:194-210.

(2.) Efstratiou A, George RC. Microbiology and epideminlogy of diphtheria. Reviews in Medical Microbiology 1996;7:31-42.

(3.) Bray JP, Burt EG, Potter EV, Poon-King T, Earle DR Epidcmic diphtheria and skin infections in Trinidad. J Infect Dis 1972;126:34-40.

(4.) Koopman JS, Campbell J. The role of cutaneous diphtheria infections in a diphtheria epidemic. J Infect Dis 1975;131:239-44.

(5.) Bonnet JM, Begg NT. Control of diphtheria; guidance for consultants in communicable disease control. Commun Dis Public Health 1999;2:242-57.

Anne-Claire de Benoist, * Joanne Margaret White, * Androulla Efstratiou, ([dagger]) Carole Kelly, ([dagger]) Ginder Mann, ([dagger]) Bernadette Nazareth, ([double dagger]) Charles James Irish, [section] Deepti Kumar, [paragraph] and Natasha Sarah Crowcroft *

* Immunisation Division, Health Protection Agency, London, United Kingdom; ([dagger]) Respiratory and Systemic Infection Laboratory, Streptococcus and Diptheria Reference Unit, Health Protection Agency, London, United Kingdom; ([double dagger]) Cambridgeshire and Peterborough Public Health Protection Unit, Huntington, United Kingdom; ([section]) Avon Health Protection Unit, Bristol, United Kingdom; and ([paragraph]) Ealing Primary Care Trust, London, United Kingdom

Ms. de Benoist was funded through the European Programme for Intervention Epidemiology by Directorate-General SANCO of the European Commission.

Ms. de Benoist worked at the Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom, asa fellow of the European Programme of Intervention Epidemiology Training. Her research interests include surveillance and field epidemiology in infectious diseases, especially gastrointestinal and vaccine-preventable diseases, in both developing and industrialized countries.

Address for correspondence: Natasha Crowcroft, Health Protection Agency, Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, NW9 5EQ, United Kingdom; fax: 00-44-0-208-200 7868; email: natasha.crowcroft@hpa.org.uk

COPYRIGHT 2004 U.S. National Center for Infectious Diseases
COPYRIGHT 2004 Gale Group

Return to Diphtheria
Home Contact Resources Exchange Links ebay